T cells (black) attack melanoma cells (red). Compared with the control group (left), T cells treated with navtemadlin were significantly more effective at killing melanoma cells, leaving very few cancer cells remaining.
Image Credit: Crompton Laboratory.
Scientific Frontline: Extended "At a Glance" Summary: p53 Activation in T-Cell Immunotherapy
The Core Concept: Temporarily activating the p53 protein during the preparation of engineered T cells enhances their resilience, reduces immune exhaustion, and significantly improves their ability to destroy tumor cells.
Key Distinction/Mechanism: Rather than introducing additional genetic modifications to boost immune cell longevity, this method uses an investigational drug called navtemadlin to block MDM2, a protein that normally suppresses p53. This temporary activation promotes the development of robust central memory T cells with higher energy reserves and increased production of cancer-fighting proteins like interferon-gamma and granzyme B.
Origin/History: Published in Frontiers in Immunology by UCLA Health researchers in October 2026, this research marks one of the first human studies to connect p53—traditionally known as the "guardian of the genome," due to its role in preventing cancer—with the prevention of T-cell exhaustion.
Major Frameworks/Components:
- Engineered T-Cell Therapies: Customizing a patient's own immune cells, such as through chimeric antigen receptor (CAR) T-cell therapy and T-cell receptor (TCR) therapy, to target tumors.
- T-Cell Exhaustion: The gradual loss of immune cell efficacy and ability to multiply following repeated exposure to cancer cells.
- p53 and MDM2 Regulation: The molecular pathway where inhibiting MDM2 temporarily boosts p53 activity to optimize T-cell maturation and metabolic capacity.
Branches of Science: Oncology, Immunology, Molecular Pharmacology, Bioengineering
Future Application: Navtemadlin or similar p53-activating drugs could be seamlessly integrated into existing T-cell manufacturing processes, creating stronger immunotherapies for both blood cancers and solid tumors without complicating the genetic engineering pipeline.
Why It Matters: T-cell exhaustion remains one of the most significant barriers to the long-term success of cancer immunotherapies. By fortifying the cells before they are infused back into the patient, this strategy could dramatically improve the durability and overall success of cancer treatments.
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a promising new strategy to make cancer-fighting immune cells stronger and potentially longer lasting, a discovery that could help improve the effectiveness of immunotherapies that use a patient's own immune cells to attack cancer.
The study, published in Frontiers in Immunology, found that temporarily activating a protein called p53, best known for its role in preventing cancer, helped immune cells develop characteristics associated with longer-lasting immune responses. The treated cells showed fewer signs of exhaustion, had greater energy reserves, and were more effective at killing melanoma cells in the laboratory.
The findings suggest that adding a drug during the preparation of engineered immune cells could offer a relatively simple way to improve existing T-cell therapies without requiring additional genetic modifications.
Engineered T-cell therapies, including chimeric antigen receptor (CAR) T-cell therapy and T-cell receptor (TCR) therapy, have transformed treatment for certain blood cancers and are increasingly being investigated for solid tumors.
These treatments involve collecting a patient's immune cells, genetically modifying them in a laboratory to recognize cancer, and then infusing them back into the patient to attack tumors.
Despite their success, one of the biggest challenges is T-cell exhaustion, which occurs when immune cells gradually lose their ability to multiply and attack tumors after repeated exposure to cancer. The process used to prepare these cells for treatment can also cause them to mature too quickly, making them less likely to survive and remain effective over time.
Scientists have been searching for ways to help these cells function longer and maintain their cancer-fighting abilities. UCLA researchers turned their attention to p53, a protein best known for its role in preventing cancer, to see whether it could help address this challenge.
What the Study
Did The researchers investigated whether temporarily activating p53, often called the "guardian of the genome" because of its role in preventing cancer, could improve how T cells develop and function.
Although p53 has been extensively studied for its ability to prevent damaged cells from becoming cancerous, its role in regulating human T cells is less understood.
To test the approach, the team collected human T cells and treated them with navtemadlin, an investigational drug that blocks another protein called MDM2, which normally keeps p53 levels under control. By blocking MDM2, the drug increases p53 activity.
Researchers compared treated and untreated cells to determine how the drug affected their development, energy production, and ability to fight cancer.
The team also genetically engineered T cells to recognize a protein found on certain melanoma cells and tested how effectively they killed cancer cells in laboratory experiments. Using specialized imaging equipment, the researchers monitored the cells for nearly 7 days.
Researchers found that temporarily activating p53 during the preparation of human T cells helped produce immune cells that were better equipped to fight cancer. The treated cells were more likely to develop into central memory T cells, which have a greater ability to survive and multiply when they encounter their target again. They also showed fewer molecular signs of exhaustion, suggesting they may be better equipped to maintain their effectiveness over time.
The cells also had greater energy reserves and were more likely to produce two important cancer-fighting proteins, interferon-gamma and granzyme B, which help immune cells coordinate an attack and destroy cancer cells.
Most importantly, when researchers tested the engineered T cells against melanoma cells, those prepared with navtemadlin were significantly more effective at killing cancer cells than untreated cells.
The treated cells began clearing cancer cells more effectively after approximately 40 hours and maintained their advantage throughout the experiment. They also showed improved cancer-fighting activity without additional interleukin-2, a protein commonly used to support T-cell growth and survival.
The researchers also found that the amount of drug used was important. At lower concentrations, navtemadlin promoted the development of healthy memory T cells without substantially reducing the overall number of viable cells. Higher concentrations, however, caused more cells to die, highlighting the need to carefully control p53 activation.
Impact of Findings
The findings suggest that temporarily activating p53 during the preparation of engineered T cells could offer a new way to improve cancer immunotherapy. Rather than developing an entirely new treatment or introducing additional genetic modifications, researchers could potentially incorporate a drug such as navtemadlin into existing manufacturing processes to produce immune cells that are better equipped to fight cancer.
“This is one of the first studies to link p53, one of the most extensively studied proteins in biology, to T-cell exhaustion in humans,” said Joseph Crompton, MD, PhD, assistant professor of surgery at the David Geffen School of Medicine at UCLA and senior author of the study. “While p53 has long been known for its role in preventing cancer, our findings suggest it may also play an important role in helping immune cells maintain their ability to fight it. This opens up a new avenue for developing more effective cancer immunotherapies.”
Funding: The study was funded in part by the American College of Surgeons, the UCLA Broad Center of Regenerative Medicine and Stem Cell Research, the UCLA Health Jonsson Comprehensive Cancer Center, the Tower Cancer Research Foundation, the Sarcoma Foundation of America, and the National Cancer Institute of the National Institutes of Health under the Early-Stage Surgeon Scientist Program.
Published in journal: Frontiers in Immunology
Authors: Alexandra Boix de Jesus, Hy B. Dao, Anthony Imani, Gabriel A. Rodriguez, Michael S. Shehata, Rachana R. Chandran, Stuart A. Fine, Sin Y. Lim, Michelle To, Serena Y. Lofftus, Nicolas Pedroncelli, Fritz C. Eilber, Brigitte N. Gomperts, Tyler R. McCaw, Cristina Puig-Saus, and Joseph G. Crompton
Source/Credit: University of California, Los Angeles / Health | Denise Heady
Edited by: Scientific Frontline
Reference Number: ongy102926_01
